DEFA14A: Scholar Rock Announces Board Changes and Withdrawal of Director Nominee Ahead of Annual Meeting

Scholar Rock Holding Corporation announces the withdrawal of Jay T. Backstrom as a director nominee and several executive appointments ahead of its Annual Meeting of Stockholders on May 22, 2025.

Summary

• Scholar Rock Holding Corporation has announced changes to its board and executive team.
• Jay T. Backstrom has transitioned from CEO and President to Senior Advisor and resigned from the Board, effective April 27, 2025.
• Consequently, he has been withdrawn as a director nominee for re-election at the Annual Meeting on May 22, 2025.
• The Board has reduced its size to nine directors and will consider only two director nominees: Srinivas Akkaraju and Joshua Reed.
• David Hallal has been appointed as the new CEO, Akshay Vaishnaw as President of Research & Development, R. Keith Woods as COO, and Vikas Sinha as CFO, all effective April 27, 2025.
• Junlin Ho will serve as the proxy holder at the Annual Meeting.
• Stockholders who have already voted do not need to take any action unless they wish to change their vote.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document primarily reports changes in personnel and board composition. While leadership transitions can create uncertainty, the company is proceeding with its Annual Meeting as planned.

Positives

• The appointment of new executives could bring fresh perspectives and strategies to the company.
• The remaining director nominees, Srinivas Akkaraju and Joshua Reed, are current members of the Board, providing continuity.

Negatives

• The resignation of Jay T. Backstrom as CEO and director could create uncertainty.
• The withdrawal of a director nominee reduces the choices available to stockholders.

Risks

• The transition in leadership could disrupt ongoing projects and strategies.
• The reduced board size could impact decision-making processes.

Future Outlook

The company is proceeding with its Annual Meeting with a revised slate of director nominees and a new executive team.

Management Comments

• The Board continues to recommend a vote FOR each of the remaining two director nominees: Srinivas Akkaraju, M.D., Ph.D. and M.P.H. and Joshua Reed, each of whom are current members of the Board.

Industry Context

Executive and board changes are common in the biopharmaceutical industry, especially for companies in the clinical stage. These changes can reflect strategic shifts or the need for different expertise as a company matures.

Comparison to Industry Standards

• Comparing Scholar Rock's board composition and executive structure to similar-sized biotech companies like Dicerna Pharmaceuticals (acquired by Novo Nordisk) or Alnylam Pharmaceuticals, one can assess whether the current leadership team aligns with industry best practices.
• For example, Dicerna had a similar number of board members prior to its acquisition, while Alnylam has a larger board reflecting its more advanced stage of development.
• Executive compensation and board diversity are also key benchmarks to consider.

Management Changes

Stakeholder Impact

• Shareholders will need to consider the changes in leadership and board composition when voting at the Annual Meeting.
• Employees may experience changes in reporting structures and responsibilities due to the new executive appointments.

Next Steps

• Stockholders will vote on the election of the two remaining director nominees at the Annual Meeting on May 22, 2025.
• The new executive team will assume their roles, effective April 27, 2025.

Key Dates

Keywords

Annual Meeting, Board of Directors, Director Nominee, Executive Appointment, Scholar Rock, Proxy Statement, Resignation